To the authors' knowledge, no studies to date have explored familial risks of nasopharyngeal carcinoma (NPC) in detail and quantified its lifetime risk in high-incidence populations. METHODS: The authors conducted a population-based case-control study of 2499 NPC cases and 2576 controls randomly selected in southern China from 2010 through 2014. Unconditional logistic regression was used to estimate multivariable-adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) associated with a family history of NPC. In addition, the authors compiled a reconstructed cohort comprising 40,781 first-degree relatives of cases and controls to calculate the lifetime cumulative risk of NPC. RESULTS: Individuals with a first-degree family history of NPC were found to be at a >4-fold risk of NPC (OR, 4.6; 95% CI, 3.5-6.1) compared with those without such a history, but had no excess risk of other malignancies. The excess risk was higher for a maternal than a paternal history and was slightly stronger for a sibling compared with a parental history, and for a sororal than a fraternal history. Among relatives of cases, the cumulative risk of NPC up to age 74 years was 3.7% (95% CI, 3.3%-4.2%), whereas that among relatives of controls was 0.9% (95% CI, 0.7%-1.2%). Cumulative risk was higher in siblings than in parents among relatives of cases, whereas no such difference was noted among relatives of controls. CONCLUSIONS: Individuals with a family history of NPC have a substantially higher risk of NPC. These relative and cumulative risk estimates can guide the development of strategies for early detection and clinical consultation in populations with a high incidence of NPC. Cancer 2017;123:2716-25.
INTRODUCTION
The elevated risk of nasopharyngeal carcinoma (NPC) among individuals with a first-degree family history of NPC has been well documented. [1] [2] [3] [4] [5] [6] [7] [8] Although the 2-fold to 20-fold [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] excess first-degree familial risk of NPC is among the highest of any malignancy, 20 inherited cancer syndromes are presumed not to account for a high percentage of cases. However, because to the best of our knowledge the majority of studies have not ascertained all first-degree relatives and are not population-based, absolute NPC risks in the general population with and without a family history in NPCendemic geographic regions, in which the great majority of NPC cases occur worldwide, 21 are largely unknown. This uncertainty precludes a formal evaluation of whether clinical assessment is necessary for this population.
Due to their familial history, relatives of patients with NPC may seek clinical consultation more frequently than the general population. However, to our knowledge, the cumulative risk of NPC among relatives of subjects with and without an NPC diagnosis, which could inform optimal, potentially relative-specific clinical assessment strategies, also has not been quantified. In a reconstructed familial cohort design, which has not been used previously in NPC-endemic areas, cumulative risks were evaluated among relatives of cases and controls. 22 Such findings can guide strategies for primary prevention, early diagnosis, and clinical consultation. Therefore, we conducted a large, population-based, case-control and reconstructed cohort study in southern China, where the world's highest incidence rates of NPC are reported to occur. [23] [24] [25] We aimed to quantify the cumulative risk of NPC and to provide evidence that can ultimately guide age-specific and relative-specific clinical management for the general population in NPC-endemic geographic regions.
MATERIALS AND METHODS

Study Population
We conducted a collaborative study entitled "NPC Genes, Environment, and EBV" (NPCGEE) in the Zhaoqing area of Guangdong Province and the Wuzhou and Guiping/Pingnan areas of Guangxi Autonomous Region. Eligible subjects were individuals aged 20 to 74 years who were officially residing within the study area at the time of diagnosis, with no history of malignant disease or congenital or acquired immunodeficiency. Detailed information regarding the study design was described previously. 26 Briefly, a total of 3027 histopathologically confirmed, first incident NPC cases were identified between 2010 and 2013 through a rapid case ascertainment network. This total closely matched the anticipated number of incident NPC cases based on historical incidence rates in the region. Of the eligible cases, 2554 individuals (84%) consented to participate. Information regarding histopathological subtype was not available from all cases. A total of 3202 controls who were frequency matched to the 5-year age and sex distribution of the cases by residential area were selected randomly every 6 months to 12 months between 2010 and 2014 from computerized, continuously updated total population registries; of these, 2648 controls (83%) consented to participate. After the exclusion of subjects with missing, ineligible, indeterminate, or poor-quality data, 2499 cases and 2576 controls remained in the analysis.
The current study was approved by the Institutional Review Boards/ethics review boards at all participating centers. All subjects provided written or oral informed consent.
Data Collection
An electronic structured questionnaire was administered to study participants by trained interviewers. Full details are provided in the Supporting Information. We used 2 approaches to validate a self-reported first-degree family history of NPC, as described in the Supporting Information.
Statistical Analysis
We used 2 complementary approaches to estimate the risk of NPC associated with a positive family history of NPC or other cancers, adjusting for potential confounders. 27, 28 The first approach was a traditional case-control analysis, wherein we used multivariable unconditional logistic regression models to estimate the associations between a positive family history of NPC or other cancers, both overall and for specific relatives. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to estimate the relative risks (see Supporting Information). To adjust for reporting bias, we also conducted a sensitivity analysis to estimate the OR adjusted for bias as a function of the sensitivity and specificity of a self-reported first-degree family history of NPC among cases and controls. In addition, to fully account for the family size and structure of each participant, and the affected relative's age at onset, 2 kin cohorts were constructed based on the self-reported family information, comprising the first-degree relatives of the cases (as the exposed cohort) and controls (as the unexposed cohort). All first-degree relatives were followed from birth until the date of the interview, death, age 74 years, or diagnosis of NPC or another cancer, whichever occurred first. We used Cox proportional hazards regression models adjusting for age (as the time scale), sex, and geographic area and stratifying baseline hazards by familial relationship to estimate hazards ratios (HRs) with 95% CIs. To avoid the influence of familial aggregation, we used the method described by Lin to account for intracluster dependence. 29 The assumption of nonproportionality of hazards was tested using graphical assessment, and a method based on Schoenfeld residuals 30 that indicated no violation (P 5 .565). Of 42,024 first-degree relatives, we excluded 1243 with an unknown age at the time of death or cancer diagnosis, leaving 40,781 relatives in the cohort analysis.
We again used 2 complementary approaches to estimate the cumulative risk of NPC. First, to quantify cumulative risks of NPC for the first-degree relatives, we multiplied their age-specific OR estimates by the agespecific NPC cumulative risks in the underlying population in 2011 (see Supporting Information Fig. S1 ). Only 2 counties in the study area with historically high NPC incidence rates had population-based cancer incidence data available, 23 potentially leading to biased estimates of NPC incidence over the entire study area. Therefore, we estimated age-specific (ages 20-74 years) general population incidence rates by dividing the annual number of incident NPC cases identified for the current study by the total person-time of the population at risk in 2011. 31 Second, to account for the family size and structure of each respondent, we used the Kaplan-Meier method to estimate the cumulative risk of NPC up to age 74 years, which is considered as the cumulative probability of NPC occurrence among relatives of cases (the exposed cohort) and of controls (the unexposed cohort) separately. The disease-specific survival curve was plotted using the Nelson-Aalen estimator. We used the log-rank test to evaluate heterogeneity of cumulative risk by familial relationship and sex of relatives, treating cases and controls separately. Table 1 shows the distribution of baseline demographic characteristics and other potential risk factors for NPC among the 2499 cases and 2576 controls. Cases and controls had similar numbers of first-degree relatives (median, 8 vs 8) (see Supporting Information Table S1 ). Cases with a first-degree family history of NPC were more likely to reside in Zhaoqing/Wuzhou than in Guiping/Pingnan. Otherwise, we found no significant differences with regard to the distribution of characteristics between familial and sporadic NPC cases (see Supporting Information Table S2 ).
RESULTS
Baseline Characteristics of Cases and Controls
Relative Risk Estimates Associated With a Positive Family History of NPC
Compared with controls, cases were 4.6 times (95% CI, 3.5-6.1 times) more likely to report a first-degree family history of NPC (10.8% of cases vs 2.7% of controls) (Table 2). The magnitude of the association was greater for having a mother (OR, 5.6) than a father (OR, 3.1) with NPC, and slightly but not significantly greater for having an affected sibling (OR, 5.1) compared with a parent (OR, 4.0) and an affected sister (OR, 5.6) compared with a brother (OR, 4.8). NPC risk increased for those with a greater number of affected relatives; the fully adjusted ORs for having 1 or at least 2 affected relatives were 4.4 (95% CI, 3.3-5.9) and 6.7 (95% CI, 2.8-16.0), respectively (P for trend < .001). A history of NPC in offspring was not associated with a significantly higher risk of NPC; however, the number of affected offspring, who were aged 22 to 24 years on average, was small. Based on the fully adjusted OR, up to 8.6% (95% CI, 5.9%-11.3%) of all incident NPC cases in the population were attributable to a first-degree family history of NPC.
In our validation study, the number of observed (self-reported) NPC cases occurring between ages 20 and 74 years among first-degree relatives of controls was slightly higher than that expected in the general population of the overall study area in 2011 (74 observed vs 59 expected among controls; standardized incidence ratio, 1.2 [P 5 .07]). A positive first-degree family history of NPC was confirmed based on cancer registry data and/or medical records for 39 of 41 cases and 5 of 5 controls, whereas a negative family history was confirmed for 50 of 52 cases and 45 of 48 controls in Sihui City. Among cases, the sensitivity and specificity for a self-reported first-degree family history of NPC were 95% (95% CI, 88%-100%) and 98% (95% CI, 94%-100%), respectively; among controls, they were 83% (95% CI, 54%-100%) and 100% (95% CI, 100%-100%), respectively. After correcting for misclassification, the OR associated with having at least 1 affected first-degree relative was 3.1.
We also investigated the association between a selfreported second-degree family history of NPC and the risk of NPC. Compared with controls, cases were 5.3 times (95% CI, 3.4-8.3 times) more likely to report a second-degree family history of NPC (4.8% of cases vs 0.9% of controls) (see Supporting Information Table S3 ). NPC risk was not found to be significantly increased among those with a positive first-degree family history of any non-NPC cancer (OR, 1.1; 95% CI, 0.9-1.3) (see Supporting Information Table S4 ).
The overall adjusted HR for NPC in first-degree relatives of cases versus controls was 4.2 (95% CI, 3.2-5.5). The HR was higher for those with an affected sibling than an affected parent, and it also was slightly higher for those with an affected mother versus a father and for those with an affected sister versus a brother (see Supporting Information Fig. S2 ).
Original Article
Cumulative Risk of NPC Associated With a Positive Family History of NPC
The estimated cumulative risk of NPC was greater for males than females with a first-degree family history of NPC. Because only 1 sister aged < 50 years diagnosed with NPC was reported among male controls, the cumulative risk in this age group was not estimated. Otherwise, between ages 20 and 74 years, the cumulative risk of NPC for males with any affected first-degree relative was 5.0% (95% CI, 3.6%-7.0%), ranging from 4.2% for those with an affected father to 6.3% for those with an affected sister ( Table 3 ). Because only 1 mother diagnosed with NPC was reported among female controls, the cumulative risk was not estimated. Otherwise, between ages 20 and 74 years, the cumulative risk of NPC for females with any affected first-degree relative was 1.9% (95% CI, 1.1%-3.2%), ranging from 0.8% for females with an affected father to 2.2% for females with an affected brother. Table 4 shows lifetime cumulative risks of NPC up to age 74 years among first-degree relatives of cases and controls in the reconstructed cohort (40,781 individuals). Among relatives of cases, the cumulative risk of NPC was 3.7% (95% CI, 3.3%-4.2%), whereas that among relatives of controls was 0.9% (95% CI, 0.7%-1.2%). The (Fig. 1) . By contrast, as expected, the cumulative risk of NPC among relatives of population-based controls did not differ between siblings (1.2% [95% CI, 0.7%-2.0%] in brothers and 0.6% [95% CI, 0.3%-1.2%] in sisters) and parents (1.3% [95% CI, 0.9%-2.0%] in fathers and 0.5% [95% CI, 0.3%-0.9%] in mothers) (P 5 .76). The cumulative risk of NPC differed significantly between fathers and brothers of cases (P<.001), but not between fathers and brothers of controls (P 5 .73). No significant differences were found between mothers and sisters of cases (P 5 .08) or controls (P 5 1.00).
DISCUSSION
In southern China, where NPC is endemic, the issue of whether a family history of NPC should be considered in risk stratification or clinical management has remained uncertain, partly due to the lack of estimates of lifetime risk among individuals with a family history. Although the association between a family history of NPC and NPC risk has been studied extensively in both NPC highincidence and low-incidence populations, to the best of our knowledge the current study is the largest case-control study to date using a strict population-based design. Because a prospective cohort study to investigate this research question is logistically impractical, a populationbased case-control study and reconstructed cohort study of relatives are the most efficient approaches. The findings of the current study demonstrate that individuals with a firstdegree family history of NPC were at a >4-fold higher risk of NPC compared with those without such a history, but had no excess risk of other malignancies. Among relatives of cases, the cumulative risk of NPC up to age 74 years was 3.7%, whereas that among relatives of controls was 0.9%. These findings may be applicable to other populations with a high incidence of NPC, such as residents of Hong Kong, Malaysia, Singapore, and Indonesia. 24, 32 We used 2 complementary approaches to estimate the relative risk associated with a positive family history of NPC. The > 4-fold increase in NPC risk noted among first-degree relatives of individuals with NPC is comparable to that reported in other studies. [2] [3] [4] [5] 9, 11, 14, 33 The restriction of the excess risk to a family history of NPC but not other non-NPC cancers is consistent with reports from Taiwan 3,11 and one report from China. 33 Yu et al and Jia et al reported that the increased risk of cancer in NPC families was restricted to NPC. 3, 33 By contrast, studies from intermediate-incidence 4 and low-incidence populations 5 demonstrated that the elevated risk among first-degree relatives was not limited to NPC but extended to other cancers, such as those of the salivary glands and cervix uteri. These findings could be due to different frequencies of NPC susceptibility genes, variations in attributable environmental or lifestyle risk factors, or both, although they also could be explained by different study designs, misclassification, or chance. Because we did not collect information regarding environmental exposures among relatives in the current study, we were unable to distinguish between the contributions of genetic susceptibility and shared environmental risk factors toward familial NPC risk. However, environmental risk factors alone are unlikely to account for such strong familial associations. In a community cohort study, Hsu et al demonstrated that the increased risk of NPC in relatives persisted, although it was attenuated, after adjustment for anti-Epstein-Barr virus antibody levels and smoking history. 2 In addition, associations between NPC risk and certain human leukocyte antigen alleles have been well established. [34] [35] [36] Taken together, these findings suggest a major contribution of genetic susceptibility to the occurrence of NPC, at least in high-incidence areas.
Four previous studies found a stronger association between NPC risk and a sibling history compared with a parental history of NPC, 11, 13, 14, 19 and 3 studies found a stronger association between NPC risk and a maternal history compared with a paternal history of NPC. 10, 12, 33 In the current study, we observed a slightly, nonsignificantly higher risk of NPC among those with an affected sibling compared with those with an affected parent (OR, 5.1 for siblings and 4.0 for parents), and the relative risk among those with an affected mother (OR, 5.6) was found to be slightly higher still. These patterns could be explained in part by shared environmental risk factors. For example, the maternal link and sibling link may be due to similar dietary habits between mother and child, and between siblings during early childhood, as suggested by the association between early childhood exposure to salt-preserved food and NPC risk, [37] [38] [39] or they could be due to chance. Our observation of slightly higher relative risks conferred by having an affected female compared with a male firstdegree relative (ie, a mother or sister compared with a father or brother, respectively) may be a chance finding, but it merits further investigation into possible mechanisms.
In contrast to prior reports from China, 14, 16 we found no significant modification of the association with a family history of NPC by environmental risk factors. This finding suggests that putative NPC susceptibility genes may act independently of environmental factors in NPC carcinogenesis. However, the small number of controls with a positive first-degree family history of NPC and the relatively low power for the test of heterogeneity make it difficult to draw any firm conclusions regarding the joint effects of family history and environmental risk factors. Pooled studies with larger sample sizes are needed to explore such interactions.
We also used 2 complementary approaches to estimate the cumulative risk of NPC. They demonstrated similar results, although each approach has its strengths and limitations. Whether close clinical surveillance for NPC may be beneficial for individuals with a family history of NPC remains under debate; cost-effectiveness studies that account for family member-specific risks are needed to answer this question. Based on the case-control study design, the findings of the current study demonstrated that between ages 20 and 74 years in a high-risk region, approximately 5.0% of men and 1.9% of women with a firstdegree family history of NPC will develop NPC, compared with 1.1% of men and 0.4% of women in the general population without such a history. We also found that the cumulative risks are greatest among those with sisters affected with NPC. Similarly, the reconstructed kin cohort approach demonstrated that the cumulative risks associated with a family history are greater in siblings than in parents. For example, 6.3% of the brothers of patients with NPC and 3.5% of sisters up to age 74 years are expected to develop NPC, compared with 3.4% of fathers and 2.5% of mothers. These results could help to guide the development of clinical management strategies or targeted populationbased screening programs.
The strengths of the current study include its large sample size, population-based design, and high participation rates in cases and controls. We obtained information regarding each relative separately by using a structured interview, and we demonstrated high accuracy of the interview for the presence of NPC among first-degree relatives. For example, the observed cumulative risk of NPC up to age 74 years among the first-degree relatives of controls was 0.9%, which is slightly higher than cumulative risks reported from a few high-incidence areas in South Asia, such as Malaysia (0.76%) and Singapore (0.67%), 24 but is similar to those from other areas in southern China, such as Hong Kong (approximately 0.9%). 32 However, the current study has a few limitations. First, we validated a selfreported family history of NPC in only 1 county, and the findings may not be generalizable to other study regions. Second, although we limited the primary analysis to firstdegree relatives to reduce recall bias, the results of our validation study demonstrated that ORs and cumulative risks would be overestimated. Nevertheless, the striking positive association persisted after adjustment for bias. Third, although all NPC cases were histopathologically confirmed, we lacked complete information regarding the histopathological subtypes; however, type II/III NPC comprises the vast majority (>95%) of NPC cases in southern China, whereas the rest are type I (keratinizing carcinoma). 40, 41 Thus, the results of the current study are expected to apply mainly to individuals with type III NPC and may not be generalizable to those with type I NPC.
Conclusions
The current large, population-based case-control study revealed a >4-fold increase in the risk of NPC among individuals with a first-degree family history of the disease. The observed association was found to be stronger for having a maternal compared with a paternal history. Because the cumulative risk of NPC increases after age 30 years, the current screening strategy recommended in China focusing on individuals aged 30 to 59 years might be appropriate but could be extended to age 69 years for those with a first-degree family history of NPC. Brothers of patients with NPC were found to have the highest lifetime cumulative risk of NPC among first-degree relatives, and thus a higher-intensity screening strategy for this substratum could be considered. The cumulative risks quantified herein, along with the results of future studies regarding other risk stratification factors and cost-benefit analyses, can guide clinical consultation and the development of surveillance policies for this important public health problem in NPC-endemic areas. 
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